Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Ultimovacs Q1 2022: Patient recruitment is progressing well

CB

Christian Binder

Redeye comments on Ultimovacs’ Q1 report; with patient recruitment for the company’s phase II trials progressing steadily, we judge. We believe the company sits on a comfortable cash cushion, providing ample funding runway through several potential major value inflection points.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers